Consolidated Statements of Stockholders Equity (Deficit) - USD ($) $ in Thousands	Common Stock Previously Reported [Member]	Common Stock Adjustment [Member]	Common Stock	Additional Paid-in Capital Previously Reported [Member]	Additional Paid-in Capital Adjustment [Member]	Additional Paid-in Capital	Stockholders' Accumulated Deficit Previously Reported [Member]	Stockholders' Accumulated Deficit	Redeemable convertible preferred stock Previously Reported [Member]	Redeemable convertible preferred stock Adjustment [Member]	Previously Reported [Member]	Adjustment [Member]	Total
Balances, at Beginning of period at Dec. 31, 2020		$ 3	$ 3	$ 10,828	$ 43,269	$ 54,097	$ (80,795)	$ (80,795)			$ (69,967)	$ 43,272	$ (26,695)
Balances, at Beginning of period (in shares) at Dec. 31, 2020	4,910,555	28,038,952	32,949,507
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of Series C redeemable convertible preferred stock upon exercise of Series C warrants						6,810							6,810
Issuance of Series C redeemable convertible preferred stock upon exercise of Series C warrants (in shares)			849,932
Issuance of common stock warrants						433							433
Exercise of stock options						10							10
Exercise of stock options (in shares)			139,578
Stock-based compensation expense						68							68
Net loss								(27,436)					(27,436)
Balances, at End of period at Mar. 31, 2021			$ 3			61,418		(108,231)					(46,810)
Balances, at End of period (in shares) at Mar. 31, 2021			33,939,017
Balances, at Beginning of period at Dec. 31, 2020									$ 43,272	$ (43,272)
Balances, at Beginning of period (in shares) at Dec. 31, 2020									30,120,057	(30,120,057)
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of common stock warrants						433							433
Stock-based compensation expense						68							68
Net loss								(27,436)					(27,436)
Balances, at Beginning of period at Dec. 31, 2021			$ 8			206,768		(181,564)					25,212
Balances, at Beginning of period (in shares) at Dec. 31, 2021			75,062,642
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Exercise of stock options						6							$ 6
Exercise of stock options (in shares)			24,434										24,434
Vesting of restricted stock units (in shares)			66,417
Stock-based compensation expense						972							$ 972
Net loss								(10,756)					(10,756)
Balances, at End of period at Mar. 31, 2022			$ 8			207,746		(192,320)					15,434
Balances, at End of period (in shares) at Mar. 31, 2022			75,153,493
Increase (Decrease) in Temporary Equity [Roll Forward]
Stock-based compensation expense						$ 972							972
Net loss								$ (10,756)					$ (10,756)